首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷

市場調查報告書

商品編碼

1955066

全球腫瘤PET（正子斷層掃描）市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析以及未來預測（2026-2034）

Oncology Positron Emission Tomography Scan Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

出版日期: 2026年01月19日 | 出版商:

Fortune Business Insights Pvt. Ltd. | 英文 165 Pages | 商品交期: 請詢問到貨日

價格

簡介目錄圖表

腫瘤PET（正子斷層掃描）市場成長驅動因子

2025年，全球腫瘤PET（正子斷層掃描）市場規模為123.1億美元。預計該市場將從2026年的130.3億美元成長到2034年的206.6億美元，在預測期（2026-2034年）內複合年增長率（CAGR）為5.93%。

2025年，北美在全球腫瘤PET掃描市場佔主導地位，市場佔有率達52.40%，這得益於其先進的診斷基礎設施、較高的癌症發病率以及對創新成像技術的積極應用。技術。

腫瘤PET是一種非侵入性分子影像技術，廣泛用於癌症的檢測、分期、治療效果評估和復發監測。全球癌症負擔日益加重、對提高診斷準確性的需求不斷增長、技術進步以及政府主導的癌症篩檢計畫是推動市場成長的關鍵因素。

市場動態

市場驅動因素

全球癌症負擔日益加重是推動市場成長的主要因素。攝護腺癌、肺癌、乳癌和大腸癌發生率的上升，推動了擴大篩檢計畫和先進診斷工具的需求激增。各國政府和醫療系統正在大力投資早期檢測措施，旨在降低死亡率和治療成本。

例如，影像學指南的更新以及用於前列腺癌的新型PET造影劑的批准，正在加速PET掃描的普及。此外，對個人化醫療和早期診斷的日益重視，也正在加速腫瘤PET掃描在各種醫療機構中的應用。

市場限制因子

PET掃描器和檢查的高成本仍然是主要的限制因素。 PET掃描儀的價格差異很大，從47.5萬美元到超過75萬美元不等，此外還需支付安裝、維護、放射性示踪劑和專業技術人員的人工成本。

不一致的保險報銷政策進一步限制了PET的普及，尤其是在發展中國家。即使在已開發市場，重複檢查和特定腫瘤適應症的保險覆蓋範圍限制也阻礙了PET的推廣應用，並對市場擴張產生負面影響。

市場機會

人工智慧（AI）與先進影像量化工具的結合帶來了巨大的成長機會。 AI驅動的PET系統能夠提高病灶偵測、腫瘤特性分析、工作流程效率和治療效果評估的準確性。

持續的技術創新、人工智慧軟體的監管批准以及下一代PET/CT系統的廣泛應用預計將推動市場發展至2034年。

市場挑戰

放射性示蹤劑的供應和供應鏈限制是重大挑戰。 FDG等放射性示蹤劑的半衰期較短，需要高效率的物流和靠近迴旋加速器設施。延誤和供應中斷會導致患者等待時間延長和檢查量減少，可能限制市場成長。

市場趨勢

向治療性診斷和個人化癌症影像的轉型

影響市場的一個關鍵趨勢是診療一體化技術的日益普及，該技術結合了診斷和標靶治療。基於PET的診療一體化試劑，特別是用於前列腺癌的PSMA基示蹤劑，能夠實現精準診斷和即時治療監測。

對個人化癌症影像和新型PET示蹤劑研發的投資增加，正在改變癌症治療管理，並推動市場長期成長。

新冠疫情的影響

由於封鎖和供應鏈中斷，新冠疫情嚴重擾亂了腫瘤PET服務。癌症篩檢和診斷程序大幅下降，導致診斷延遲。

全球調查顯示，2020年中PET掃描量下降超過65%，凸顯了疫情的短期負面影響。然而，隨著疫情後經濟復甦和人們對癌症診斷的重新關注，市場動能正在恢復。

市場區隔分析

依資金來源劃分

市場依資金來源分為公共醫療保險及私人醫療保險/自費支出。在美國、日本、印度和巴西等國家，由於就診快速、醫療品質高、等待時間短，私人醫療機構佔市場主導地位。

即使在公立醫療體系內，隨著資金投入的增加和國家癌症控制計畫的推進，PET掃描的普及程度也在不斷提高。

依服務提供者劃分

服務提供者包括醫院、診斷中心等。

預計到2025年，醫院將佔最大市場佔有率，這得益於其先進的影像基礎設施和熟練的醫護人員。
由於成本效益高、專業化程度高、等待時間短，診斷中心預計將實現最快成長。

區域展望

北美市場引領市場，預計2025年市場規模將達到65億美元，2026年將達到68.2億美元，主要得益於高癌症發生率和技術的快速普及。
歐洲佔了相當大的市場佔有率，這得益於其健全的醫療保健體系和不斷增加的新型PET示踪劑的批准。
亞太地區預計到2034年將實現最高的複合年增長率，主要得益於不斷擴大的醫療基礎設施和政府主導的各項舉措。
拉丁美洲以及中東和非洲地區預計將保持穩定成長，這主要歸功於癌症發生率的上升和醫療保健投資的增加。

市場分析、洞察與預測：依資金來源劃分
- 公共醫療保險/私人醫療保險/自付費用
市場分析、洞察與預測：依服務提供者劃分
- 醫院
- 診斷中心
- 其他
市場分析、洞察與預測：依地區劃分
- 北美
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲

第六章北美腫瘤PET（正子斷層掃描）市場分析：洞察與預測（2021-2034）

依國家劃分
- 美國州/省
- 加拿大

第七章歐洲腫瘤PET（正子斷層掃描）市場分析：洞察與預測（2021-2034）

依國家劃分
- 英國
- 德國
- 法國
- 西班牙
- 義大利
- 斯堪的納維亞
- 其他歐洲國家

第八章亞太地區腫瘤PET（正子斷層掃描）市場分析：洞察與預測（2021-2034）

依國家劃分
- 日本
- 中國
- 印度
- 澳大利亞
- 東南亞
- 其他亞洲國家太平洋

第九章拉丁美洲腫瘤PET（正子斷層掃描）市場分析：洞察與預測（2021-2034）

依國家劃分
- 巴西
- 墨西哥
- 其他拉丁美洲國家

第十章中東與非洲腫瘤PET（正子斷層掃描）市場分析：洞察與預測（2021-2034）

依國家劃分
- 海灣合作委員會
- 南非
- 其他中東和非洲國家

第11章競爭分析

全球市場佔有率分析(2025年)
企業簡介
- GE Healthcare
- Sonic Healthcare Limited
- Oncovision
- Koninklijke Philips N.V.
- Apex Radiology
- Alliance Medical Limited
- Novant Health
- Canon Medical Systems
- Dignity Health
- Concord Medical
- Siemens Healthcare Limited
- Mediworks
- Other Prominent Players

簡介目錄圖表

Product Code: FBI113540

Growth Factors of oncology positron emission tomography (PET) scan Market

The global oncology positron emission tomography (PET) scan market was valued at USD 12.31 billion in 2025. The market is projected to grow from USD 13.03 billion in 2026 to USD 20.66 billion by 2034, exhibiting a CAGR of 5.93% during the forecast period (2026-2034).

North America dominated the global oncology PET scan market with a 52.40% market share in 2025, supported by advanced diagnostic infrastructure, high cancer prevalence, and strong adoption of innovative imaging technologies.

Oncology PET is a non-invasive molecular imaging technique widely used for cancer detection, staging, therapy assessment, and recurrence monitoring. Rising global cancer burden, increasing demand for diagnostic accuracy, technological advancements, and government-led cancer screening programs are key factors driving market growth.

Market Dynamics

Market Drivers

The rising global burden of cancer is a primary driver of market growth. Increasing incidence of cancers such as prostate, lung, breast, and colorectal cancer has led to a surge in screening programs and demand for advanced diagnostic tools. Governments and healthcare systems are investing heavily in early detection initiatives to reduce mortality and treatment costs.

For instance, updated imaging guidelines and approvals of novel PET imaging agents for prostate cancer have strengthened PET adoption. Additionally, the growing emphasis on personalized medicine and early diagnosis is accelerating the use of oncology PET scans across healthcare settings.

Market Restraints

The high cost of PET scanners and procedures remains a significant restraint. PET scanners can cost between USD 475,000 and over USD 750,000, excluding expenses related to installation, maintenance, radiotracers, and skilled personnel.

Inconsistent reimbursement policies further limit accessibility, particularly in developing economies. Even in developed markets, limited insurance coverage for repeat scans and certain oncology indications restricts utilization, negatively impacting market expansion.

Market Opportunities

The integration of artificial intelligence (AI) and advanced image quantification tools presents a major growth opportunity. AI-enabled PET systems improve lesion detection, tumor characterization, workflow efficiency, and treatment response evaluation.

Continuous innovation, regulatory approvals of AI-based software, and growing adoption of next-generation PET/CT systems are expected to support market development through 2034.

Market Challenges

Radiotracer availability and supply chain constraints pose critical challenges. Radiotracers such as FDG have short half-lives, requiring efficient logistics and proximity to cyclotron facilities. Delays or disruptions can lead to longer patient wait times and reduced scan volumes, limiting market growth.

Market Trends

Shift Toward Theranostics and Personalized Oncology Imaging

A key trend shaping the market is the growing adoption of theranostics, which combines diagnostics and targeted therapy. PET-based theranostic agents, especially PSMA-based tracers for prostate cancer, enable precise diagnosis and real-time therapy monitoring.

Increasing investments in personalized oncology imaging and the development of novel PET tracers are transforming cancer management and driving long-term market growth.

Impact of COVID-19

The COVID-19 pandemic significantly disrupted oncology PET services due to lockdowns and supply chain interruptions. Cancer screening and diagnostic procedures declined sharply, leading to delayed diagnoses.

According to global surveys, PET scan volumes dropped by over 65% in mid-2020, highlighting the pandemic's negative short-term impact. However, post-pandemic recovery and renewed focus on cancer diagnostics have restored market momentum.

Segmentation Analysis

By Source of Payment

The market is segmented into public and private health insurance/out-of-pocket. The private segment dominated the market due to faster access, premium-quality care, and reduced waiting times, especially in countries such as the U.S., Japan, India, and Brazil.

Public healthcare systems are also expanding PET access through increased funding and national cancer control programs.

By Service Provider

Based on service providers, the market includes hospitals, diagnostic centers, and others.

Hospitals accounted for the largest share in 2025 due to advanced imaging infrastructure and skilled personnel.
Diagnostic centers are expected to register the fastest growth owing to cost efficiency, specialization, and shorter waiting periods.

Regional Outlook

North America led the market with USD 6.5 billion in 2025 and USD 6.82 billion in 2026, driven by high cancer prevalence and rapid technology adoption.
Europe held a substantial share due to strong healthcare systems and increasing approvals of novel PET tracers.
Asia Pacific is projected to record the highest CAGR through 2034, supported by healthcare infrastructure expansion and government initiatives.
Latin America and Middle East & Africa are expected to witness steady growth due to rising cancer incidence and improving healthcare investments.

Competitive Landscape

Key players operating in the global oncology PET scan market include GE Healthcare, Siemens Healthcare Limited, Oncovision, Koninklijke Philips N.V., Canon Medical Systems, and Sonic Healthcare Limited. These companies focus on product innovation, strategic collaborations, and regulatory approvals to strengthen their market presence.

Conclusion

The global oncology positron emission tomography scan market is set to grow steadily from USD 12.31 billion in 2025 to USD 20.66 billion by 2034, driven by the rising cancer burden, technological advancements, and increasing focus on personalized oncology imaging. While high equipment costs and radiotracer supply challenges remain key concerns, innovations in AI-enabled imaging, theranostics, and expanding screening programs are expected to sustain long-term market growth. North America will continue to dominate the market, while Asia Pacific is anticipated to emerge as the fastest-growing region during the forecast period.

Segmentation By Source of Payment

Public
Private Health Insurance/Out-of-pocket

By Service Providers

Hospitals
Diagnostic Centers
Others

By Region

North America (By Source of Payment, Service Providers, and Country)
- U.S.
- Canada
Europe (By Source of Payment, Service Providers, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
Asia Pacific (By Source of Payment, Service Providers, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Source of Payment, Service Providers, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Source of Payment, Service Providers, and Country/Sub-region)
- GCC
- South Africa
Middle East & Africa

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Prevalence of Cancer, Key Countries
4.2. New Product Launches, By Key Players
4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
4.4. Technological Advancements in Oncology PET

5. Global Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

5.1. Market Analysis, Insights and Forecast - By Source of Payment
- 5.1.1. Public
- 5.1.2. Private Health Insurance/Out-of-pocket
5.2. Market Analysis, Insights and Forecast - By Service Providers
- 5.2.1. Hospitals
- 5.2.2. Diagnostic Centers
- 5.2.3. Others
5.3. Market Analysis, Insights and Forecast - By Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Latin America
- 5.3.5. Middle East & Africa

6. North America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

6.1. Market Analysis, Insights and Forecast - By Source of Payment
- 6.1.1. Public
- 6.1.2. Private Health Insurance/Out-of-pocket
6.2. Market Analysis, Insights and Forecast - By Service Providers
- 6.2.1. Hospitals
- 6.2.2. Diagnostic Centers
- 6.2.3. Others
6.3. Market Analysis, Insights and Forecast - By Country/Sub-region
- 6.3.1. U.S.
- 6.3.2. Canada

7. Europe Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

7.1. Market Analysis, Insights and Forecast - By Source of Payment
- 7.1.1. Public
- 7.1.2. Private Health Insurance/Out-of-pocket
7.2. Market Analysis, Insights and Forecast - By Service Providers
- 7.2.1. Hospitals
- 7.2.2. Diagnostic Centers
- 7.2.3. Others
7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.3.1. U.K.
- 7.3.2. Germany
- 7.3.3. France
- 7.3.4. Spain
- 7.3.5. Italy
- 7.3.6. Scandinavia
- 7.3.7. Rest of Europe

8. Asia Pacific Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

8.1. Market Analysis, Insights and Forecast - By Source of Payment
- 8.1.1. Public
- 8.1.2. Private Health Insurance/Out-of-pocket
8.2. Market Analysis, Insights and Forecast - By Service Providers
- 8.2.1. Hospitals
- 8.2.2. Diagnostic Centers
- 8.2.3. Others
8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.3.1. Japan
- 8.3.2. China
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. Southeast Asia
- 8.3.6. Rest of Asia Pacific

9. Latin America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

9.1. Market Analysis, Insights and Forecast - By Source of Payment
- 9.1.1. Public
- 9.1.2. Private Health Insurance/Out-of-pocket
9.2. Market Analysis, Insights and Forecast - By Service Providers
- 9.2.1. Hospitals
- 9.2.2. Diagnostic Centers
- 9.2.3. Others
9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.3.1. Brazil
- 9.3.2. Mexico
- 9.3.3. Rest of Latin America

10. Middle East & Africa Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

10.1. Market Analysis, Insights and Forecast - By Source of Payment
- 10.1.1. Public
- 10.1.2. Private Health Insurance/Out-of-pocket
10.2. Market Analysis, Insights and Forecast - By Service Providers
- 10.2.1. Hospitals
- 10.2.2. Diagnostic Centers
- 10.2.3. Others
10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.3.1. GCC
- 10.3.2. South Africa
- 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

11.1. Global Market Share Analysis (2025)
11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 11.2.1. GE Healthcare
  - 11.2.1.1. Overview
  - 11.2.1.2. Products
  - 11.2.1.3. SWOT Analysis
  - 11.2.1.4. Recent Developments
  - 11.2.1.5. Strategies
  - 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Sonic Healthcare Limited
  - 11.2.2.1. Overview
  - 11.2.2.2. Products
  - 11.2.2.3. SWOT Analysis
  - 11.2.2.4. Recent Developments
  - 11.2.2.5. Strategies
  - 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Oncovision
  - 11.2.3.1. Overview
  - 11.2.3.2. Products
  - 11.2.3.3. SWOT Analysis
  - 11.2.3.4. Recent Developments
  - 11.2.3.5. Strategies
  - 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Koninklijke Philips N.V.
  - 11.2.4.1. Overview
  - 11.2.4.2. Products
  - 11.2.4.3. SWOT Analysis
  - 11.2.4.4. Recent Developments
  - 11.2.4.5. Strategies
  - 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Apex Radiology
  - 11.2.5.1. Overview
  - 11.2.5.2. Products
  - 11.2.5.3. SWOT Analysis
  - 11.2.5.4. Recent Developments
  - 11.2.5.5. Strategies
  - 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Alliance Medical Limited
  - 11.2.6.1. Overview
  - 11.2.6.2. Products
  - 11.2.6.3. SWOT Analysis
  - 11.2.6.4. Recent Developments
  - 11.2.6.5. Strategies
  - 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Novant Health
  - 11.2.7.1. Overview
  - 11.2.7.2. Products
  - 11.2.7.3. SWOT Analysis
  - 11.2.7.4. Recent Developments
  - 11.2.7.5. Strategies
  - 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Canon Medical Systems
  - 11.2.8.1. Overview
  - 11.2.8.2. Products
  - 11.2.8.3. SWOT Analysis
  - 11.2.8.4. Recent Developments
  - 11.2.8.5. Strategies
  - 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Dignity Health
  - 11.2.9.1. Overview
  - 11.2.9.2. Products
  - 11.2.9.3. SWOT Analysis
  - 11.2.9.4. Recent Developments
  - 11.2.9.5. Strategies
  - 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Concord Medical
  - 11.2.10.1. Overview
  - 11.2.10.2. Products
  - 11.2.10.3. SWOT Analysis
  - 11.2.10.4. Recent Developments
  - 11.2.10.5. Strategies
  - 11.2.10.6. Financials (Based on Availability)
- 11.2.11. Siemens Healthcare Limited
  - 11.2.11.1. Overview
  - 11.2.11.2. Products
  - 11.2.11.3. SWOT Analysis
  - 11.2.11.4. Recent Developments
  - 11.2.11.5. Strategies
  - 11.2.11.6. Financials (Based on Availability)
- 11.2.12. Mediworks
  - 11.2.12.1. Overview
  - 11.2.12.2. Products
  - 11.2.12.3. SWOT Analysis
  - 11.2.12.4. Recent Developments
  - 11.2.12.5. Strategies
  - 11.2.12.6. Financials (Based on Availability)
- 11.2.13. Other Prominent Players
  - 11.2.13.1. Overview
  - 11.2.13.2. Products
  - 11.2.13.3. SWOT Analysis
  - 11.2.13.4. Recent Developments
  - 11.2.13.5. Strategies
  - 11.2.13.6. Financials (Based on Availability)

簡介目錄圖表

List of Tables

Table 1: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
Table 2: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
Table 3: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Region, 2021-2034
Table 4: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
Table 5: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
Table 6: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 7: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
Table 8: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
Table 9: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
Table 10: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
Table 11: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
Table 12: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
Table 13: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
Table 14: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
Table 15: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
Table 16: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
Table 17: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
Table 18: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

Figure 1: Global Oncology Positron Emission Tomography Scan Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
Figure 2: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025 & 2034
Figure 3: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025 & 2034
Figure 4: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Region, 2025 & 2034
Figure 5: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
Figure 6: North America Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
Figure 7: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
Figure 8: North America Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
Figure 9: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country, 2025 & 2034
Figure 10: North America Oncology Positron Emission Tomography Scan Market Value Share (%), By Country, 2025
Figure 11: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
Figure 12: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
Figure 13: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
Figure 14: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
Figure 15: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
Figure 16: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2025
Figure 17: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
Figure 18: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
Figure 19: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
Figure 20: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
Figure 21: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
Figure 22: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2025
Figure 23: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
Figure 24: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
Figure 25: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
Figure 26: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
Figure 27: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
Figure 28: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2025
Figure 29: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
Figure 30: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
Figure 31: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
Figure 32: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
Figure 33: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
Figure 34: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2025
Figure 35: Global Oncology Positron Emission Tomography Scan Market Share (%), By Company, 2025